Effect of erobixibat on liver dysfunction in patients with chronic constipation

Effect of erobixibat on liver dysfunction in patients with chronic constipation - Effect of erobixibat on liver dysfunction in patients with chronic constipation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039833

Enrollment

Registered

2020-04-01

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver dysfunciton

Interventions

Elobixibat 10mg 6months Magnesium oxide 2g 6months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: New patients with chronic constipation Informed consent Oral intake PS 0-2

Exclusion criteria

Exclusion criteria: Cancer patients Child pugh grade C Obstructive jaundice Severe renal impairment or dialysis pregnancy Infection Mental illness

Design outcomes

Primary

Measure	Time frame
Improvement of biochemical parameter (AST, ALT, Alb, Tbil and PT) after 6 months	—

Countries

Japan

Contacts

Public ContactAkira Asai

Osaka Medical College 2nd department of internal medicine

in2108@osaka-med.ac.jp0726831221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026